Safusidenib is an investigational new drug that is being evaluated by AnHeart Therapeutics and the Daiichi Sankyo Company for the treatment of IDH1-mutant glioma.…
Safusidenib is an investigational new drug that is being evaluated by AnHeart Therapeutics and the Daiichi Sankyo Company for the treatment of IDH1-mutant glioma. It is a isocitrate dehydrogenase 1 inhibitor.
Clinical trials Safusidenib is in phase 3 clinical trials for IDH1-mutant glioma.
References
Gebaseerd op: Wikipedia — Safusidenib · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.